(MNT) - earned 33 cents per share in this year's quarter, 18% above estimates

Mentor Corporation has exceeded analyst expectations in six out of the past seven quarters, with three of them surprising by double-digits. Two analysts have raised their numbers for this year, while one has done so for next year. Over the past 30 days, this year's estimates have increased 3.5% to $1.17 per share, while next year's numbers have jumped 9.5% to $1.50 per share. The stock is currently trading at 30.4x next year's estimates, above the projected long-term growth rate of 17%, giving the stock a PEG ratio of 1.79. Full Analysis Mentor Corporation (MNT) engages in the development, manufacture, and marketing of various products serving the aesthetic medicine market in the United States. It offers breast implants, body contouring, and other aesthetics, which includes facial aesthetics products. The company develops, produces, and markets various breast implants, including saline-filled implants and silicone gel-filled implants; body contouring products, including liposuction products and disposable supplies; and Puragen, a nonanimal-based hyaluronic acid dermal filler. It also provides offers software, consulting, and business management tools for plastic surgeons. MNT reported a strong fiscal first-quarter earnings report. Mentor said it earned 33 cents per share in this year's quarter, 18% above estimates. Net sales grew 7 percent to $79.4 million from $74.1 million. Looking ahead, Mentor reaffirmed its full-year revenue guidance of between $290 million and $305 million. Wall Street is looking for sales of $300.5 million. "During the quarter we recorded solid operating results as we continued to grow our core breast, facial, and body aesthetics business," commented Joshua H. Levine, President and Chief Executive Officer of Mentor. "Following the successful divestiture of Mentor's urology business this quarter, we began to restructure our operations to rationalize our corporate infrastructure and improve our efficiency and profitability. We see significant opportunities for growth and are confident that our pure-play position in aesthetic medicine will drive long-term shareholder value." The company is exploring potential acquisitions, strategic alliances or licensing deals that would help it expand its reach in the cosmetic procedures industry. The CEO said that his focus is on products that are on the market or in late-stage clinical development. Mentor has exceeded analyst expectations in six out of the past seven quarters, with three of them surprising by double-digits. Two analysts have raised their numbers for this year, while one has done so for next year. Over the past 30 days, this year's estimates have increased 3.5% to $1.17 per share, while next year's numbers have jumped 9.5% to $1.50 per share. The stock is currently trading at 30.4x next year's estimates, above the projected long-term growth rate of 17%, giving the stock a PEG ratio of 1.79. Note: The Zacks Rank is a very sensitive indicator that can change frequently for an individual stock. This important indicator is updated daily on Zacks.com and is available to Zacks Premium subscribers. As such, it is prudent to check the site for the latest Zacks Rank on the stocks highlighted in this section. Simply click the link for the stock or enter the symbol in the ticker entry box in the upper left hand corner of the web site. Content Courtesy: Zacks Investment Research #1 Ranked Stocks Highlight Archive To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions. | Blog Home| VitalStocks Home